8-K: Arcturus Therapeutics Reports Q2 2026 Results, Regains Global Rights

Arcturus Therapeutics announced its second quarter 2026 financial results, detailing progress in its ARCT-032 and ARCT-810 drug candidates, and the strategic regaining of global rights to its KOSTAIVE and infectious disease vaccine portfolio.

Summary

• Arcturus Therapeutics reported its financial results for the quarter ended June 30, 2026.
• The company is advancing its ARCT-032 Phase 2 cystic fibrosis study, with a decision to proceed to Phase 3 expected in Q4 2026.
• Enrollment and dosing for the ARCT-810 Phase 2 study for OTC deficiency are complete, with data and regulatory plans expected in Q3 2026.
• Arcturus has regained global rights to its KOSTAIVE and infectious disease vaccine portfolio following a termination and settlement agreement with CSL Seqirus.
• This agreement includes a $12 million cash payment to Arcturus and release from approximately $16 million in liabilities and R&D credits.
• Cash and cash equivalents were $191.5 million as of June 30, 2026.
• Revenue for the quarter was $3.0 million, a decrease from $28.3 million in the prior year period.
• Net loss for the quarter was $23.8 million, or $0.84 per share, compared to a net loss of $9.2 million, or $0.34 per share, in the prior year period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant pipeline progress and strategic asset recovery, balanced by a widening net loss and reduced revenue.

Positives

• ARCT-032 Phase 2 study enrollment remains on schedule, with a decision to proceed to Phase 3 expected in Q4 2026.
• ARCT-810 Phase 2 study enrollment and dosing are complete, with data and regulatory plans to be communicated in Q3 2026.
• Arcturus regained global rights to KOSTAIVE and its infectious disease vaccine portfolio.
• The termination and settlement agreement with CSL Seqirus provides Arcturus with $12 million in cash and release from $16 million in liabilities and R&D credits.
• The company maintains a strong balance sheet with a cash runway of over two and a half years through year-end 2028.
• Thermo Fisher Scientific collaboration will provide Phase 3 manufacturing and clinical research services for ARCT-032.

Negatives

• Revenue for the three months ended June 30, 2026, was $3.0 million, a significant decrease from $28.3 million in the same period of 2025.
• Net loss for the three months ended June 30, 2026, was $23.8 million, an increase from $9.2 million in the same period of 2025.
• Net loss per share for the quarter was $0.84, compared to $0.34 in the prior year quarter.
• Cash and cash equivalents decreased by $39.4 million from December 31, 2025, to June 30, 2026, due to clinical development activities.

Risks

• Forward-looking statements are subject to substantial risks and uncertainties, including the likelihood of success of the Company's pipeline (including ARCT-032 and ARCT-810).
• There is a risk that clinical data, including interim data, may not be predictive of future clinical results.
• The company's ability to reach important clinical and regulatory milestones for its rare disease pipeline is subject to risk.
• General business and economic conditions could impact the company's performance.
• The company's ability to develop, commercialize, or seek partnership opportunities related to KOSTAIVE and its other infectious disease vaccine programs carries inherent risks.

Future Outlook

The company expects to communicate data and a regulatory plan for ARCT-810 in Q3 2026 and make a decision to proceed to Phase 3 for ARCT-032 in Q4 2026. Arcturus anticipates a cash runway of over two and a half years through year-end 2028.

Management Comments

• "We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States, Israel, and Turkey."
• "With dosing completed of all subjects in our ARCT-810 Phase 2 OTC deficiency study, we look forward to sharing the data and regulatory plan later this quarter."
• "We are also pleased to regain strategic control of KOSTAIVE and our infectious disease vaccine portfolio, enhancing our ability to increase the value of our validated sa-mRNA vaccine platform."
• "We remain focused on disciplined execution and capital allocation as we advance our rare disease programs. The CSL Seqirus termination and settlement agreement strengthens our financial position, and the Thermo Fisher collaboration supports execution of late-stage development for our CF program. We continue to maintain a strong balance sheet and cash runway of over two and a half years through year end 2028, allowing our company to reach important clinical and regulatory milestones for its rare disease pipeline."

Industry Context

StockSavvy.ai notes that Arcturus Therapeutics' focus on mRNA therapeutics for rare diseases aligns with a significant trend in the biopharmaceutical industry, where mRNA technology is being explored beyond vaccines. The company's strategic asset recovery and collaborations with major players like Thermo Fisher Scientific are key indicators of its positioning within this evolving landscape.

Legal Proceedings

• The termination and settlement agreement with CSL Seqirus resolves an arbitration relating to a European regulatory approval milestone payment.

Stakeholder Impact

• Shareholders may be impacted by the increased net loss and decreased revenue, though pipeline progress and strategic asset recovery offer potential future value.
• Employees may be affected by the company's focus on disciplined capital allocation.
• Partners and collaborators (e.g., Thermo Fisher Scientific) are integral to the advancement of key pipeline programs.

Next Steps

• Communicate data and regulatory plan for ARCT-810 in Q3 2026.
• Make a decision to proceed to Phase 3 for ARCT-032 in Q4 2026.
• Evaluate opportunities to maximize future value of KOSTAIVE and the broader infectious disease vaccine portfolio.
• Conduct Phase 3 program for ARCT-032 through Thermo Fisher's PPD clinical research business, subject to positive Phase 2 results and regulatory approval.
• Thermo Fisher will receive exclusive commercial manufacturing rights for ARCT-032 under a separate commercial agreement, subject to regulatory approval.

Key Dates

Recommendation

The filing presents a mixed picture. While pipeline progress in ARCT-032 and ARCT-810, along with the strategic regaining of valuable assets, are positive developments, the significant increase in net loss and decrease in revenue are concerning. The company's long cash runway provides a buffer, but the worsening financial performance warrants a cautious 'hold' stance until further clinical and financial milestones are achieved.

Keywords

mRNA therapeutics, Cystic Fibrosis, Ornithine Transcarbamylase Deficiency, rare disease, vaccine platform, clinical trials, financial results, drug development